Selinexor Plus Ruxolitinib for Myelofibrosis

Phase 3, active-controlled in JAK inhibitor-naive myelofibrosis with objective MRI/CT SVR35 at Week 24 supports a credible readout. However, ruxolitinib alone is an effective comparator, so selinexor must add spleen benefit beyond a strong standard backbone, and co-endpoint/safety execution add risk.

Phase 3 and objective MRI/CT SVR35 endpoint support readout quality, but ruxolitinib is active in both arms, so selinexor must add clear spleen benefit over a strong standard comparator. Co-primary symptom endpoint adds disclosure risk though the market question targets SVR.

Phase 3 randomized trial in JAKi-naive MF testing selinexor + rux vs placebo + rux. Primary SVR35 at week 24 is objective, standard endpoint with MRI/CT measurement. Prior selinexor data supportive for spleen responses. Active/not recruiting, primary completion Feb 2026 (now 3 months past) with no disclosed issues points to likely positive readout.

Phase 3 trial in JAKi-naive myelofibrosis; standard objective SVR35 endpoint at week 24 via MRI/CT. Active not recruiting after primary completion date indicates mature data but undisclosed; combo on ruxolitinib backbone with validated symptom/spleen measures supports moderate success odds.

Karyopharm reported Phase 3 SENTRY topline results on March 24, 2026. The trial successfully met the SVR35 at week 24 endpoint (50% vs 28%, p<0.0001). Although the second co-primary endpoint evaluating symptom score (Abs-TSS) was missed, the specific SVR35 endpoint queried in this market achieved clear statistical significance, making a YES resolution virtually certain.

Topline results reported on March 24, 2026, confirmed that the Phase 3 SENTRY trial met its SVR35 co-primary endpoint. SVR35 at week 24 was 50% for selinexor plus ruxolitinib vs 28% for placebo plus ruxolitinib (p<0.0001). Although the trial missed the other co-primary endpoint (Abs-TSS), this market resolves based solely on the SVR35 outcome, which was definitively positive.

Phase 3 selinexor+ruxolitinib in JAKi-naïve myelofibrosis. Primary endpoint SVR35 at Week 24. Trial past primary completion (Feb 2026) with no topline release, often a negative signal. Selinexor has notable toxicity (nausea, cytopenias). Historical Phase 3 success for oncology add-on combinations is ~40-50%. Intrinsic probability estimated at 40%.

Phase 3 add-on to ruxolitinib in JAKi-naïve MF. Prior Phase 2 SVR35 ~58% but small sample. Recent similar Phase 3 trials (pelabresib, navitoclax) failed to improve SVR35 over ruxolitinib alone (~40%). No results 3 months after primary completion raises concern. Estimate 38% success probability.

Phase 2 JAZZ trial demonstrated ~65% SVR35 for selinexor+ruxolitinib in JAKi-naive MF, justifying Phase 3. However, selinexor's GI and hematologic toxicity often necessitates dose modifications, which can blunt efficacy in larger registrational studies. Ruxolitinib alone achieves ~40-50% SVR35, so the bar for improvement is clear but the combo's tolerability poses execution risk.

Selinexor+ ruxolitinib vs placebo+ruxolitinib in JAKi-naïve MF. Phase 2 data showed encouraging SVR rates but small sample. Selinexor carries significant toxicity (thrombocytopenia, GI) that may cause dose reductions offsetting efficacy. XPO1 inhibition is unproven in MF. SVR35 is objective/validated endpoint, which helps, but superiority over ruxolitinib monotherapy is a high bar. ~48% intrinsic YES probability.

Selinexor's XPO1 inhibition synergizes with ruxolitinib in preclinical MF models. The MANIFEST-2 Phase 2 data showed promising SVR35 rates (~30-40%) in JAKi-naïve patients. While Phase 3 is rigorous, the mechanistic rationale and prior efficacy signal support a positive outcome, though safety/tolerability remains a key risk factor for trial completion and statistical significance.

Phase 3 tests selinexor+ruxolitinib in JAKi-naïve MF. SVR35 at wk24 is stringent. XPO1 inhibitors carry notable toxicity, risking dose reductions that blunt efficacy. Trial is 90 days past completion; data is mature but unannounced. Historical combo challenges in MF suggest modest success odds.

Selinexor adds a novel mechanism to ruxolitinib in JAK‑inhibitor‑naïve MF. Prior selinexor monotherapy showed modest spleen responses; combination may improve SVR35 but safety concerns and many Phase 3 combos have failed. Expected incremental benefit ~10‑15% over ruxolitinib alone suggests a >50% chance of meeting the SVR35 endpoint, but uncertainty about tolerability keeps probability modest.

Selinexor adds toxicity risk and modest mechanistic benefit over ruxolitinib alone; prior JAK‑inhibitor‑naïve cohorts respond to ruxolitinib, making incremental spleen reduction uncertain. Phase‑3 SVR35 endpoint is standard, but limited early data suggest only a modest chance of surpassing ruxolitinib alone.

Phase 3 myelofibrosis trial testing selinexor+ruxolitinib vs placebo+ruxolitinib in JAK-naïve patients. SVR35 at Week 24 is a well-validated regulatory endpoint. XPO1 inhibition has rationale in MF, but selinexor's narrow therapeutic index and prior toxicity profile in other indications raise execution risk. Primary completion was Feb 2026 (91 days past), suggesting data may be near or delayed. No prior Phase 2 MF data disclosed. Symptom endpoint co-primary adds pressure. Disclosure risk moderate-to-high given past-due completion date.

Primary completion was 90 days ago with no topline readout—unusual delay suggests potential issues with data lock or regulatory review. Selinexor (XPO1 inhibitor) has modest efficacy in prior myelofibrosis data; SVR35 rates were ~27% in Phase 2, below typical JAK inhibitor benchmarks (~42% for ruxolitinib alone). Adding selinexor to ruxolitinib in JAK-naïve patients is mechanistically plausible but unproven. The co-primary endpoint structure adds complexity; missing either endpoint could derail regulatory success even if SVR35 hits. Sponsor KPTI has limited late-stage execution track record. 3

Phase 3 combo of Selinexor (XPO1 inhibitor) with ruxolitinib in JAK inhibitor-naïve MF tests a novel mechanism. SVR35 is validated but demanding. Selinexor has mixed track record in other cancers; combination efficacy unproven. Trial past estimated completion (-91 days) may signal delays or data review. Given Phase 3 risks, intrinsic success odds around 45%.

Phase 3 myelofibrosis trial combining selinexor (XPO1 inhibitor) with ruxolitinib standard of care. SVR35 at week 24 is a validated objective endpoint. Rational mechanism but selinexor carries GI toxicity baggage from prior trials. JAK inhibitor-naïve population appropriate. Trial past primary completion, results likely imminent. Historical Phase 3 oncology success ~50-55%; selinexor's tolerability concerns reduce this slightly.